Health Care·Pharmaceuticals·$183.6B
Novo Nordisk A/S is a global healthcare company specializing in pharmaceuticals, particularly in diabetes care and hormone replacement therapies. With a market cap of $170 billion, it plays a significant role in the healthcare sector, focusing on innovative treatments that address chronic conditions, which are increasingly prevalent worldwide.
EPS
Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
Total revenue reflects the company's sales performance and market demand for its products, which is crucial for assessing growth.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
63%
Avg EPS Surprise
+35.76%
Avg Stock Reaction
-1.40%
In Q3 2025, Novo Nordisk reported an EPS of $0.69, falling short of the $0.77 estimate, indicating potential challenges in meeting market expectations. The revenue figures were not disclosed, leaving some uncertainty about overall performance.
Management Promises & Guidance
Analysts are cautiously optimistic about Novo Nordisk's upcoming earnings, expecting a recovery in EPS and revenue growth. The consensus estimates suggest that the company may be regaining momentum after a mixed performance in previous quarters.
Bull Case
If Novo Nordisk exceeds the EPS and revenue estimates, it could signal strong demand for its diabetes treatments and other products, boosting investor confidence.
Bear Case
Conversely, if the company misses expectations again, it could raise concerns about its growth trajectory and market competitiveness, leading to a negative reaction from investors.
EPS
$6.96Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$72.0BTotal revenue reflects the company's sales performance and market demand for its products, which is crucial for assessing growth.
The print will turn on these two things.
Q1
Will EPS exceed the consensus estimate of $6.96?
A strong EPS performance would indicate effective cost management and revenue generation, which is crucial for investor confidence.
Q2
What are the revenue figures compared to the expected $72.0B?
Revenue performance will provide insights into market demand for Novo Nordisk's products and overall business health.
Why consensus could be wrong
The consensus may underestimate the potential for revenue growth driven by new product launches and expanding market share in diabetes care.
Supporting Evidence
Recent trends in diabetes management suggest increasing demand for innovative treatments, which could boost sales beyond expectations.
The company's strong pipeline of new products may not be fully reflected in current revenue estimates.
Key Risk
If new product sales significantly exceed expectations, it could challenge the current consensus on revenue growth.
Pre-commit to what would confirm each case.
This quarter's results will be critical in determining whether Novo Nordisk can maintain its growth trajectory amid competitive pressures.
Bull Confirmed If
EPS growth exceeding $6.96 and revenue surpassing $72.0B would confirm strong operational performance.
Bear Confirmed If
An EPS below $6.96 and revenue falling short of $72.0B would raise concerns about the company's growth prospects.
Implied Move
±5%
Historical Avg
±3.8%
The options market is pricing in a potential move of about 5% in either direction following the earnings report, indicating uncertainty among investors.
Options are pricing ±7.2% while NVO has averaged ±3.8% over the last 8 prints — setup is pricing rich.
Cross-company pattern from 30 similar setups.
Prior-quarter miss setup in Health Care
n=30Fade rate: 7 of 30 (23%)
This setup has occurred 30 times across Health Care in the last 2 years. 23 of 30 (77%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.9%, with a raw directional average of +0.6% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Novo Nordisk beats expectations, history suggests the stock could rise by an average of 3.9%, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical patterns indicating an average drop of around 0.6% following such outcomes.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026